A combination of immunotherapy and targeted cancer treatment given before and after surgery may reduce the risk of recurrence and improve survival in ...

Accelerated water-bath thawing, completed in about 25 minutes, may help streamline clinical workflows and support efficient patient management -- Label update includes data showing that product ...

Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...

CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...

Detailed price information for Theralase Techs Inc (TLTFF) from The Globe and Mail including charting and trades.

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

NEW YORK, (February 19, 2026) – Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder ...

Kamat has received research funding from Arquer Diagnostics, EnGene, FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, and SWOG; and ...